said Samira Sakhia, President and CEO of Knight. Minjuvi ® (tafasitamab ... Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics ...

Multinational pharmaceutical firms, particularly U.S. giants, are increasingly recognizing China's burgeoning innovative drug sector as a strategic goldmine to bolster their global competitiveness.

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.

United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

Ms. Collins will also serve as interim CEO. Dr. Khandros will remain on Nutcracker Therapeutics’ board of directors. Dr. Khandros co-founded Nutcracker Therapeutics in 2018, alongside Chief ...

United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million.

United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million.

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

“We are thrilled to welcome Michael to Avalo’s Board of Directors during this pivotal time in our Company’s growth,” said Dr. Garry Neil, CEO of Avalo Therapeutics. “Michael’s ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

Crispr Therapeutics said Chief Operating Officer Julianne Bruno would depart the company to pursue other opportunities, effective April 11. Bruno joined the gene-editing company in 2019 and stepped ...